Featured Research

from universities, journals, and other organizations

Hide-and-seek: Altered HIV can't evade immune system

Date:
September 28, 2011
Source:
Johns Hopkins Medical Institutions
Summary:
Researchers have modified HIV in a way that makes it no longer able to suppress the immune system. Their work could remove a major hurdle in HIV vaccine development and lead to new treatments.

A model of HIV showing the organization of membrane associated cholesterol (in yellow).
Credit: Image courtesy of Johns Hopkins Medical Institutions/Jenny Wang

Researchers at Johns Hopkins have modified HIV in a way that makes it no longer able to suppress the immune system. Their work, they say in a report published online September 19 in the journal Blood, could remove a major hurdle in HIV vaccine development and lead to new treatments.

Related Articles


"Something about the HIV virus turns down the immune response, rather than triggering it, making it a tough target for vaccine development," says David Graham, Ph.D., assistant professor of molecular and comparative pathobiology and medicine. "We now seem to have a way to sidestep this barrier," he adds.

Typically, when the body's immune system cells encounter a virus, they send out an alarm by releasing chemicals called interferons to alert the rest of the body to the presence of a viral infection. When the immune cells encounter HIV, however, they release too many interferons, become overwhelmed and shut down the subsequent virus-fighting response.

The researchers had learned from other studies that when human immune cells (white blood cells) are depleted of cholesterol, HIV can no longer infect them. It turns out the coat that surrounds and protects the HIV viral genome also is rich in cholesterol, leading the Johns Hopkins team to test whether viruses lacking cholesterol could still infect cells at all.

The researchers treated HIV with a chemical to remove cholesterol from the viral coat. Then they introduced either the cholesterol-diminished or normal HIV to human immune cells growing in culture dishes, and measured how the cells responded. The cells exposed to cholesterol-diminished HIV didn't release any initial-response interferons, whereas the cells exposed to normal HIV did.

"The altered HIV doesn't overwhelm the system and instead triggers the innate immune response to kick in, like it does with any first virus encounter," says Graham.

Next, the researchers checked to see if cholesterol-diminished HIV activates so-called adaptive immune responses -- the responses that help the body remember specific pathogens long-term so the body develops immunity and counters future infections. To do this, they put normal HIV or cholesterol-diminished HIV into blood samples, which contain all the different cells needed for an adaptive immune response.

More specifically, they tested blood samples from people with previous exposure to HIV in order to see if their blood could mount an adaptive immune response. Blood samples were used from 10 HIV positive people and from 10 people repeatedly exposed to HIV who weren't infected. The researchers didn't expect the HIV-positive blood to respond to either version of HIV because of the severely damaged immune systems of HIV patients. However, when cholesterol-diminished HIV was introduced to the non-infected HIV blood in a tube, the cells of the adaptive immune response reacted against the virus. By altering the virus, explains Graham, the researchers were able to reawaken the immune system's response against HIV and negate HIV's immunosuppressive properties.

"In addition to vaccine applications, this study opens the door to developing drugs that attack the HIV viral coat as an adjunct therapy to promote immune system detection of the virus," says Graham.

This research was supported by funds from the Wellcome Trust and the National Institutes of Health.

Contributors to the research include David Graham and Veronica Aquino of The Johns Hopkins University; Adriano Boasso, Caroline Royle and Spyridon Doumazos of Imperial College; Mara Biasin, Luca Piacentini, Barbara Tavano and Mario Clerici of Università degli Studi di Milano; Dietmar Fuchs of Innsbruck Medical University; Francesco Mazzotta and Sergio Lo Caputo of Ospedale S. M. Annunziata and Gene Shearer of the National Cancer Institute.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Boasso, C. M. Royle, S. Doumazos, V. N. Aquino, M. Biasin, L. Piacentini, B. Tavano, D. Fuchs, F. Mazzotta, S. Lo Caputo, G. M. Shearer, M. Clerici, D. R. Graham. Over-activation of plasmacytoid dendritic cell inhibits anti-viral T-cell responses: a model for HIV immunopathogenesis. Blood, 2011; DOI: 10.1182/blood-2011-03-344218

Cite This Page:

Johns Hopkins Medical Institutions. "Hide-and-seek: Altered HIV can't evade immune system." ScienceDaily. ScienceDaily, 28 September 2011. <www.sciencedaily.com/releases/2011/09/110928105909.htm>.
Johns Hopkins Medical Institutions. (2011, September 28). Hide-and-seek: Altered HIV can't evade immune system. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/09/110928105909.htm
Johns Hopkins Medical Institutions. "Hide-and-seek: Altered HIV can't evade immune system." ScienceDaily. www.sciencedaily.com/releases/2011/09/110928105909.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins